Correlation Between Protagenic Therapeutics and Sino Biopharmaceutica

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Protagenic Therapeutics and Sino Biopharmaceutica at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Protagenic Therapeutics and Sino Biopharmaceutica into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Protagenic Therapeutics and Sino Biopharmaceutical Ltd, you can compare the effects of market volatilities on Protagenic Therapeutics and Sino Biopharmaceutica and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Protagenic Therapeutics with a short position of Sino Biopharmaceutica. Check out your portfolio center. Please also check ongoing floating volatility patterns of Protagenic Therapeutics and Sino Biopharmaceutica.

Diversification Opportunities for Protagenic Therapeutics and Sino Biopharmaceutica

0.75
  Correlation Coefficient

Poor diversification

The 3 months correlation between Protagenic and Sino is 0.75. Overlapping area represents the amount of risk that can be diversified away by holding Protagenic Therapeutics and Sino Biopharmaceutical Ltd in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Sino Biopharmaceutical and Protagenic Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Protagenic Therapeutics are associated (or correlated) with Sino Biopharmaceutica. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Sino Biopharmaceutical has no effect on the direction of Protagenic Therapeutics i.e., Protagenic Therapeutics and Sino Biopharmaceutica go up and down completely randomly.

Pair Corralation between Protagenic Therapeutics and Sino Biopharmaceutica

Given the investment horizon of 90 days Protagenic Therapeutics is expected to under-perform the Sino Biopharmaceutica. In addition to that, Protagenic Therapeutics is 3.15 times more volatile than Sino Biopharmaceutical Ltd. It trades about -0.18 of its total potential returns per unit of risk. Sino Biopharmaceutical Ltd is currently generating about -0.27 per unit of volatility. If you would invest  834.00  in Sino Biopharmaceutical Ltd on November 2, 2024 and sell it today you would lose (109.00) from holding Sino Biopharmaceutical Ltd or give up 13.07% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthSignificant
Accuracy90.48%
ValuesDaily Returns

Protagenic Therapeutics  vs.  Sino Biopharmaceutical Ltd

 Performance 
       Timeline  
Protagenic Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Protagenic Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's forward indicators remain fairly strong which may send shares a bit higher in March 2025. The current disturbance may also be a sign of long term up-swing for the company investors.
Sino Biopharmaceutical 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Sino Biopharmaceutical Ltd has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's primary indicators remain fairly strong which may send shares a bit higher in March 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Protagenic Therapeutics and Sino Biopharmaceutica Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Protagenic Therapeutics and Sino Biopharmaceutica

The main advantage of trading using opposite Protagenic Therapeutics and Sino Biopharmaceutica positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Protagenic Therapeutics position performs unexpectedly, Sino Biopharmaceutica can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sino Biopharmaceutica will offset losses from the drop in Sino Biopharmaceutica's long position.
The idea behind Protagenic Therapeutics and Sino Biopharmaceutical Ltd pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.

Other Complementary Tools

Share Portfolio
Track or share privately all of your investments from the convenience of any device
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Transaction History
View history of all your transactions and understand their impact on performance
Money Managers
Screen money managers from public funds and ETFs managed around the world
Volatility Analysis
Get historical volatility and risk analysis based on latest market data